Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib for advanced oesophago-gastric cancer
ACTRN12612000239864Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in gastroesophageal adenocarcinoma and oesophagogastric undifferentiated carcinoma comparing Regorafenib with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Nov 2012; status: completed.
02
Drugs
regorafenib
03
Conditions
gastroesophageal adenocarcinomaoesophagogastric undifferentiated carcinoma
Beyond the preview
Go deeper on ACTRN12612000239864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000239864.